In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG, with a price target of CHF160.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that indicate strong potential for Galderma Group AG’s stock. The US sales volumes for Nemluvio are aligning with the base case projections, supporting the $134 million forecast for the third quarter. This performance suggests that Nemluvio’s success could provide a cushion against broader market uncertainties, potentially adding to the company’s total revenues.
Furthermore, insights from the EADV congress highlight Nemluvio’s relevance in addressing key medical concerns, such as itch, which is a significant topic among physicians. The prescription trends, particularly the percentage of prescriptions accounting for two pens, are crucial indicators of market recovery post-holiday impacts. These factors collectively support the positive outlook and justify the Buy rating for Galderma Group AG.
In another report released on September 16, Goldman Sachs also maintained a Buy rating on the stock with a CHF160.00 price target.